Innate Pharma SA (FR:IPH) has released an update.
Innate Pharma SA reports promising results from its Phase 2 TELLOMAK study, indicating that its drug lacutamab shows significant anti-tumor activity in treating mycosis fungoides, a type of cutaneous T-cell lymphoma. The treatment was effective regardless of patients’ baseline KIR3DL2 expression levels and demonstrated a favorable safety profile, suggesting potential as a new therapy for patients with advanced stages of the disease.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
